Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jul;72(1):129–133. doi: 10.1038/bjc.1995.288

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.

H Skomedal 1, G Kristensen 1, A Helland 1, J M Nesland 1, S Kooi 1, A L Børresen 1, R Holm 1
PMCID: PMC2034131  PMID: 7599041

Abstract

Primary carcinomas from 46 patients were screened for TP53 alterations. Immunohistochemistry demonstrated nuclear TP53 protein accumulation in 22 (48%) cases using the polyclonal CM1 antiserum, whereas 15 (33%) cases showed positive nuclear staining with the mononuclear antibody PAb 1801. Constant denaturant gel electrophoresis (CDGE) was used to screen 27 of the vaginal carcinomas for mutations in the conserved regions of the TP53 gene (exons 5-8). Six of these tumours (22%) contained mutations: four were found in exon 5 and two in exon 8. A total of 50% of the primary vaginal carcinomas carried a TP53 alteration. These results indicate that TP53 abnormalities may be involved in the development of these tumours. However, there was no significant association between TP53 abnormalities and survival.

Full text

PDF
130

Images in this article

131Figure 1
on p.131
132Figure 2
on p.132

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agoff S. N., Hou J., Linzer D. I., Wu B. Regulation of the human hsp70 promoter by p53. Science. 1993 Jan 1;259(5091):84–87. doi: 10.1126/science.8418500. [DOI] [PubMed] [Google Scholar]
  2. Andersen T. I., Holm R., Nesland J. M., Heimdal K. R., Ottestad L., Børresen A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer. 1993 Sep;68(3):540–548. doi: 10.1038/bjc.1993.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bosari S., Viale G., Radaelli U., Bossi P., Bonoldi E., Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol. 1993 Nov;24(11):1175–1179. doi: 10.1016/0046-8177(93)90212-y. [DOI] [PubMed] [Google Scholar]
  4. Bur M. E., Perlman C., Edelmann L., Fey E., Rose P. G. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol. 1992 Jul;98(1):81–87. doi: 10.1093/ajcp/98.1.81. [DOI] [PubMed] [Google Scholar]
  5. Busby-Earle R. M., Steel C. M., Williams A. R., Cohen B., Bird C. C. Papillomaviruses, p53, and cervical cancer. Lancet. 1992 May 30;339(8805):1350–1350. [PubMed] [Google Scholar]
  6. Børresen A. L., Hovig E., Smith-Sørensen B., Malkin D., Lystad S., Andersen T. I., Nesland J. M., Isselbacher K. J., Friend S. H. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8405–8409. doi: 10.1073/pnas.88.19.8405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Condie A., Eeles R., Borresen A. L., Coles C., Cooper C., Prosser J. Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. Hum Mutat. 1993;2(1):58–66. doi: 10.1002/humu.1380020111. [DOI] [PubMed] [Google Scholar]
  8. Crook T., Wrede D., Tidy J. A., Mason W. P., Evans D. J., Vousden K. H. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet. 1992 May 2;339(8801):1070–1073. doi: 10.1016/0140-6736(92)90662-m. [DOI] [PubMed] [Google Scholar]
  9. Finlay C. A., Hinds P. W., Tan T. H., Eliyahu D., Oren M., Levine A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988 Feb;8(2):531–539. doi: 10.1128/mcb.8.2.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993 Feb;8(2):307–318. [PubMed] [Google Scholar]
  11. Gronostajski R. M., Goldberg A. L., Pardee A. B. Energy requirement for degradation of tumor-associated protein p53. Mol Cell Biol. 1984 Mar;4(3):442–448. doi: 10.1128/mcb.4.3.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hall P. A., McKee P. H., Menage H. D., Dover R., Lane D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 1993 Jan;8(1):203–207. [PubMed] [Google Scholar]
  13. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  14. Helland A., Holm R., Kristensen G., Kaern J., Karlsen F., Trope C., Nesland J. M., Børresen A. L. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol. 1993 Oct;171(2):105–114. doi: 10.1002/path.1711710207. [DOI] [PubMed] [Google Scholar]
  15. Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994 Sep;22(17):3551–3555. [PMC free article] [PubMed] [Google Scholar]
  16. Holm R., Skomedal H., Helland A., Kristensen G., Børresen A. L., Nesland J. M. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol. 1993 Jan;169(1):21–26. doi: 10.1002/path.1711690105. [DOI] [PubMed] [Google Scholar]
  17. Hovig E., Smith-Sørensen B., Brøgger A., Børresen A. L. Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutat Res. 1991 Jan;262(1):63–71. doi: 10.1016/0165-7992(91)90108-g. [DOI] [PubMed] [Google Scholar]
  18. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  19. Hultman T., Ståhl S., Hornes E., Uhlén M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res. 1989 Jul 11;17(13):4937–4946. doi: 10.1093/nar/17.13.4937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ikenberg H., Runge M., Göppinger A., Pfleiderer A. Human papillomavirus DNA in invasive carcinoma of the vagina. Obstet Gynecol. 1990 Sep;76(3 Pt 1):432–438. [PubMed] [Google Scholar]
  21. Kastan M. B., Zhan Q., el-Deiry W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., Fornace A. J., Jr A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992 Nov 13;71(4):587–597. doi: 10.1016/0092-8674(92)90593-2. [DOI] [PubMed] [Google Scholar]
  22. Kern S. E., Kinzler K. W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991 Jun 21;252(5013):1708–1711. doi: 10.1126/science.2047879. [DOI] [PubMed] [Google Scholar]
  23. Kohler M. F., Marks J. R., Wiseman R. W., Jacobs I. J., Davidoff A. M., Clarke-Pearson D. L., Soper J. T., Bast R. C., Jr, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst. 1993 Sep 15;85(18):1513–1519. doi: 10.1093/jnci/85.18.1513. [DOI] [PubMed] [Google Scholar]
  24. Kohler M. F., Nishii H., Humphrey P. A., Saski H., Marks J., Bast R. C., Clarke-Pearson D. L., Boyd J., Berchuck A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol. 1993 Sep;169(3):690–694. doi: 10.1016/0002-9378(93)90644-x. [DOI] [PubMed] [Google Scholar]
  25. Lane D. P., Crawford L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979 Mar 15;278(5701):261–263. doi: 10.1038/278261a0. [DOI] [PubMed] [Google Scholar]
  26. Lane D. P. The regulation of p53 function: Steiner Award Lecture. Int J Cancer. 1994 Jun 1;57(5):623–627. doi: 10.1002/ijc.2910570502. [DOI] [PubMed] [Google Scholar]
  27. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  28. Marchetti A., Buttitta F., Pellegrini S., Campani D., Diella F., Cecchetti D., Callahan R., Bistocchi M. p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 1993 Oct 1;53(19):4665–4669. [PubMed] [Google Scholar]
  29. Marks J. R., Davidoff A. M., Kerns B. J., Humphrey P. A., Pence J. C., Dodge R. K., Clarke-Pearson D. L., Iglehart J. D., Bast R. C., Jr, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991 Jun 1;51(11):2979–2984. [PubMed] [Google Scholar]
  30. Mies C., Houldsworth J., Chaganti R. S. Extraction of DNA from paraffin blocks for Southern blot analysis. Am J Surg Pathol. 1991 Feb;15(2):169–174. doi: 10.1097/00000478-199102000-00010. [DOI] [PubMed] [Google Scholar]
  31. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  32. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989 Dec 7;342(6250):705–708. doi: 10.1038/342705a0. [DOI] [PubMed] [Google Scholar]
  33. Oka K., Nakano T., Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer. 1993 Jul 1;72(1):160–164. doi: 10.1002/1097-0142(19930701)72:1<160::aid-cncr2820720130>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  34. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993 Apr 29;362(6423):857–860. doi: 10.1038/362857a0. [DOI] [PubMed] [Google Scholar]
  35. Pride G. L., Schultz A. E., Chuprevich T. W., Buchler D. A. Primary invasive squamous carcinoma of the vagina. Obstet Gynecol. 1979 Feb;53(2):218–225. [PubMed] [Google Scholar]
  36. Purdie C. A., O'Grady J., Piris J., Wyllie A. H., Bird C. C. p53 expression in colorectal tumors. Am J Pathol. 1991 Apr;138(4):807–813. [PMC free article] [PubMed] [Google Scholar]
  37. Scheffner M., Münger K., Byrne J. C., Howley P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5523–5527. doi: 10.1073/pnas.88.13.5523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Seto E., Usheva A., Zambetti G. P., Momand J., Horikoshi N., Weinmann R., Levine A. J., Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12028–12032. doi: 10.1073/pnas.89.24.12028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Yu C. C., Wilkinson N., Brito M. J., Buckley C. H., Fox H., Levison D. A. Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium. Histopathology. 1993 Oct;23(4):367–371. doi: 10.1111/j.1365-2559.1993.tb01221.x. [DOI] [PubMed] [Google Scholar]
  40. el-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992 Apr;1(1):45–49. doi: 10.1038/ng0492-45. [DOI] [PubMed] [Google Scholar]
  41. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES